Business Wire
17 Mar 2026, 20:40 UTC · 28w ago
Verdict
Headline takes no side. We score AGEN +0.50 across one claim — strongly bullish.
+0.50strongly bullish
More positive than 70% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish
Agenus will present preliminary results from the BBoPCO study evaluating botensilimab and balstilimab in first-line MSS CRC at the AACR Annual Meeting 2026.
More positive than 65% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 70% of ticker scores this week
The company is announcing the presentation of preliminary results from a study on its cancer treatment combination.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
7h ago
+109.5%
Price agrees with the score
$8.36 vs $3.99 close before publication (Mar 17) · not market-adjusted
AGEN chart →
